Abstract-Prostaglandin (PG)E 2 has multiple actions that may affect blood pressure. It is synthesized from arachidonic acid by the sequential actions of phospholipases, cyclooxygenases, and PGE synthases. Although microsomal PGE synthase (mPGES)1 is the only genetically verified PGE synthase, results of previous studies examining the consequences of mPGES1 deficiency on blood pressure (BP) are conflicting. To determine whether genetic background modifies the impact of mPGES1 on BP, we generated mPGES1 Ϫ/Ϫ mice on 2 distinct inbred backgrounds, DBA/1lacJ and 129/SvEv. On the DBA/1 background, baseline BP was similar between wild-type (WT) and mPGES1 Ϫ/Ϫ mice. By contrast, on the 129 background, baseline BPs were significantly higher in mPGES1 Ϫ/Ϫ animals than WT controls. During angiotensin II infusion, the DBA/1 mPGES1 Ϫ/Ϫ and WT mice developed mild hypertension of similar magnitude, whereas 129-mPGES1 Ϫ/Ϫ mice developed more severe hypertension than WT controls. DBA/1 animals developed only minimal albuminuria in response to angiotensin II infusion. By contrast, WT 129 mice had significantly higher levels of albumin excretion than WT DBA/1 and the extent of albuminuria was further augmented in 129 mPGES1 Ϫ/Ϫ animals. In WT mice of both strains, the increase in urinary excretion of PGE 2 with angiotensin II was attenuated in mPGES1 Ϫ/Ϫ animals. Urinary excretion of thromboxane was unaffected by angiotensin II in the DBA/1 lines but increased more than 4-fold in 129 mPGES1 Ϫ/Ϫ mice. These data indicate that genetic background significantly modifies the BP response to mPGES1 deficiency. Exaggerated production of thromboxane may contribute to the robust hypertension and albuminuria in 129 mPGES1-deficient mice. Key Words: prostanoids Ⅲ PGE synthase Ⅲ blood pressure Ⅲ strain Ⅲ hypertension P rostaglandin (PG)E 2 is a key product of the cyclooxygenase (COX) pathway of arachidonic acid metabolism. This lipid mediator has diverse actions that include cytoprotective functions in the gastrointestinal tract, regulating smooth muscle tone in airways and vasculature, modulating the immune system, and triggering febrile responses in the brain. [1] [2] [3] In the kidney, PGE 2 is among the most abundant metabolites of arachidonic acid and thus has a significant capacity to influence renal blood flow, sodium excretion, and regulation of blood pressure. 4 These actions may be through direct effects on renal vascular tone 5,6 and epithelial function 7,8 and indirectly through its actions to trigger renin release at the macula densa. 9 -11 PGE 2 is produced by a series of 3 enzymatic reactions: release of arachidonic acid from membrane phospholipids by the actions of phospholipases, conversion of arachidonic acid to unstable endoperoxide intermediates by COXs (COX-1 and -2), and, finally, isomerization of PGH 2 to PGE 2 by terminal PGE synthases (PGESs). The temporal and spatial properties of PGE 2 synthesis are determined by the regulated expression of each of the enzymes involved in this cascade. The first PGE synthase to be identified was microsomal PGE synthase (mPGES)1, 12 and to date it remains the only genetically verified PGE synthase. Other putative PGE synthases including mPGES2 and cytosolic PGES (cPGES) have been described based on their capacity to generate PGE 2 in vitro. 13, 14 However, recent evidence indicates that neither of these proteins function as PGE synthases in vivo. 15, 16 Studies using mPGES1 Ϫ/Ϫ mice indicate that mPGES1 is responsible for the late phase of PGE 2 synthesis during inflammation via a pathway that depends on COX-2. 17 Febrile responses to LPS are also mediated by mPGES1, 18 and mPGES1 is the source of PGE 2 that facilitates acute inflammatory pain. 17 Expression of mPGES1 is markedly upregulated in synovial tissues in arthritis, 19 contributing to the pathogenesis of joint inflammation and swelling. 17 Taken together, these observations suggest that inhibition of mPGES1 might be useful for the treatment of inflammation and pain, providing a more limited therapeutic target than nonsteroidal antiinflammatory drugs (NSAIDs) or COX-2 inhibitors that cause a more global suppression of prostanoid synthesis. Moreover, because blockade of mPGES1 would not directly affect synthesis of PGI 2 , an important vasodilator and antiaggregant compound in the vasculature, adverse
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The effects of mPGES1 deficiency on blood pressure and atherosclerosis have also been examined in several previous studies. For example, in a mouse model of atherosclerosis, the absence of mPGES1 was associated with attenuated atherogenesis. 20 On the other hand, studies of blood pressure regulation in mPGES1-deficient mice have yielded conflicting results, wherein mPGES1-deficient mice have been reported to have normal 20 -23 or reduced 24, 25 baseline blood pressures with normal or exaggerated responses to high-salt feeding. 21, 24 Moreover, one group has reported that these animals have increased susceptibility to angiotensin (Ang) IIdependent hypertension. 24 The genetic background of these various mPGES1-deficient mouse lines were all different. Because genetic background can have a marked influence on the phenotypes of genetically modified mice, 26 -28 we considered the possibility that the variable blood pressure responses observed in studies of mPGES1 Ϫ/Ϫ mice might be related to effects of strain-specific genetic modifiers. To address this issue, we generated mPGES1 Ϫ/Ϫ mice on 2 distinct inbred backgrounds, DBA/1lacJ (DBA/1) and 129/SvEv (129) and compared blood pressure at baseline and during Ang IIdependent hypertension. We find strong effects of genetic background to influence the consequences of mPGES1 deficiency on blood pressure, albuminuria, and the generation of other vasoactive prostanoids.
Methods

Animals
Production of inbred DBA/1 mice with targeted disruption of the mPGES1 (Ptges1) gene using embryonic stem cells derived from DBA/1lacJ inbred mice has been described previously. 17 129/SvEv mPGES1 Ϫ/Ϫ and mPGES1 ϩ/ϩ mice were generated by backcrossing the mPGES1 mutation onto the 129/SvEv genetic background for more than eight generations. Inbred DBA/1lacJ and 129/SvEv mPGES1 Ϫ/Ϫ and mPGES1 ϩ/ϩ male mice generated by intercrossing mPGES1 ϩ/Ϫ mice of each strain were used for the studies described here. Animals were maintained in the animal facility of the Durham Veterans Affairs Medical Center and studied between 2 and 4 months of age. The experimental procedures described below were approved by the respective institutional care and use committees of the Durham Veterans Affairs and Duke University Medical Centers. Mice were fed a normal chow diet (0.4% NaCl; LabDiet, Richmond, Ind).
Radiotelemetry Measurements of Intraarterial Pressure
Blood pressure was measured in conscious mice by radiotelemetry using TA11PA-C10 transmitters (Data Sciences International, St Paul, Minn) as described previously. 29, 30 Mice were allowed to recover for 7 days after surgery to regain their normal circadian rhythms before experiments were initiated. During blood pressure measurements, mice were housed in a monitoring room in the animal facility where quiet is maintained and no other activities are permitted. Data were collected continuously with sampling every 5 minutes for 10-second intervals using Dataquest A.R.T. software (Data Sciences International).
Ang II-Induced Hypertension
Baseline blood pressure was recorded for 3 consecutive days, and then an osmotic minipump (Alzet model 2004, DURECT, Cupertino, Calif) infusing Ang II (Sigma, St Louis, Mo) at a rate of 1000 ng/kg per minute was implanted subcutaneously, as described previously, 30 and blood pressure measurements continued for 3 weeks.
Reverse Transcription and Real-Time Quantitative PCR
Total RNA was extracted (Tri-Reagent, Sigma) from mouse kidneys and reverse transcription and real-time PCR were performed as previously described. 31 Primers and dual-labeled probe (5Ј-FAM, 3Ј-TAMRA) targeting renin were synthesized based on previously published sequences. 32 Primer-probe sets for COX-1 (assay ID Mm00477214_m1) and COX-2 (assay ID Mm00478374_m1) were purchased from Applied Biosystems (Foster City, Calif).
Urinary Excretion of Albumin and Prostanoid Metabolites
Twenty-four-hour urine samples were collected by metabolic cage at baseline and after 3 weeks of Ang II infusion. Urine samples were centrifuged briefly to remove particulate matter and then immediately aliquoted and frozen at Ϫ80°C until assay. Urinary albumin excretion was measured using a specific ELISA assay for mouse albumin (Albuwell, Exocell, Philadelphia, Pa). Stable prostanoid metabolites (13,14- [prostaglandin I 2 ] ) in urine were measured using specific competitive enzyme immunoassays for each molecule (Cayman Chemical, Ann Arbor, Mich). Creatinine levels in urine were assessed using an alkaline picrate assay (Creatinine Companion, Exocell Inc, Philadelphia, Pa).
Statistical Analyses
All data are presented as meansϮSEM. Differences between groups were analyzed by unpaired t test or 2-way ANOVA, followed by Bonferroni post hoc test, as indicated, using GraphPad Prism software version 4.00 (GraphPad Software, San Diego, Calif). Differences within groups, before and after Ang II infusion, were analyzed by paired t test. A probability value of Ͻ0.05 was considered significant.
Results
We first measured blood pressures in the different mouse lines using radiotelemetry. At baseline, blood pressures in the wild-type (WT) 129 mice (113Ϯ1 mm Hg) were significantly higher than the WT DBA/1 animals (105Ϯ1 mm Hg; PϽ0.001). As shown in Figure 1 , there were no differences in blood pressure between DBA/1 WT and mPGES1
Ϫ/Ϫ mice (mean arterial pressure: 105Ϯ1 versus 107Ϯ1 mm Hg). By contrast, baseline blood pressures were significantly higher in the 129-mPGES1 Ϫ/Ϫ animals (119Ϯ2 mm Hg) compared to the 129-WT controls (113Ϯ1 mm Hg; Pϭ0.008).
It has been suggested that stimulation of PGE 2 synthesis may attenuate blood pressure elevation in various hypertensive states. 33 Therefore, we next investigated the consequences of mPGES1 deficiency on Ang II-induced hypertension. As shown in Figure 2A , continuous infusion of Ang II increased blood pressure by 30 to 40 mm Hg over the first 3 to 4 days in the WT DBA/1 mice, followed by a waning of the blood pressure level over the next week, achieving a new, more modestly elevated level by the end of the infusion period. The pattern and magnitude of the hypertensive response to chronic Ang II was virtually identical in the DBA/1 mice lacking mPGES1, and, thus, the average of the mean arterial pressures for the 3 weeks of Ang II infusion were similar in the DBA/1 WT (123Ϯ2 mm Hg) and mPGES1-deficient mice (124Ϯ3 mm Hg; Figure 2B ). As shown in Figure 2A and 2B, the extent of the blood pressure elevation in the WT 129 mice was significantly greater than the WT DBA/1 animals (145Ϯ4 versus 123Ϯ2 mm Hg; PϽ0.001). Moreover, the marked elevation in blood pressure in the 129-WT group was sustained throughout the 3 weeks of infusion ( Figure 2A ). The 129-mPGES1 Ϫ/Ϫ group developed hypertension that was significantly more severe compared to their 129-WT littermates (160Ϯ4 versus 145Ϯ4 mm Hg, Pϭ0.01; Figure 2B ).
As shown in Figure 3 (left), levels of renin mRNA expression were significantly higher in kidneys from mPGES1 Ϫ/Ϫ DBA/1 than their WT controls at baseline (172Ϯ10 versus 100Ϯ13% of WT, PϽ0.05). This baseline difference was not seen in the 129 mice (100Ϯ11 versus 92Ϯ12% of WT). Renin mRNA expression was suppressed significantly and to similar levels in both the DBA/1 (37Ϯ10 versus 57Ϯ16% of WT baseline; WT PϽ0.05 versus baseline) and 129 mice (44Ϯ7 versus 36Ϯ8% of WT baseline; PϽ0.01 versus baseline) during Ang II infusion.
To determine whether mPGES1 affects kidney damage induced by Ang II, we measured urinary albumin excretion at baseline and after 3 weeks of Ang II infusion. Basal levels of albumin excretion were similar in DBA and 129 WT mice (50Ϯ18 versus 15Ϯ4 g/24 hour) and were unaffected by mPGES1 deletion in both strains of mice (DBA: 37Ϯ7; 129: 17Ϯ3 g/24 hours) (data not shown). With Ang II infusion, urinary albumin excretion increased only modestly in the WT DBA/1 animals (103Ϯ22 g/24 hours) and levels of albuminuria were basically unaffected by the absence of mPGES1 in the DBA/1-mPGES1 Ϫ/Ϫ group (114Ϯ23 g/24 hours; Figure 4 ). 
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By contrast, Ang II caused marked proteinuria in the WT 129 mice such that their levels of albumin excretion (514Ϯ106 g/24 hours) were significantly higher than the WT DBA/1 group (Pϭ0.002), as shown in Figure 4 . The extent of albuminuria was further augmented in the 129 mPGES1 Ϫ/Ϫ animals (1167Ϯ164 g/24 hour; Pϭ0.003 versus WT).
To examine whether the absence of mPGES1 affected prostanoid metabolism and whether this might be affected by genetic background, we measured urinary prostanoid excretion in the various lines at baseline and during Ang II infusion. At baseline, urinary PGE 2 excretion was similar in DBA and 129 WT mice (813Ϯ120 versus 808Ϯ137 pg/mg creatinine, Figure 5 ). Mice lacking mPGES1 had reduced baseline PGE 2 excretion compared to WT, although the difference did not reach statistical significance in 129 animals (DBA: 398Ϯ87 pg/mg creatinine, Pϭ0.01; 129: 550Ϯ119 pg/mg creatinine, Pϭ0.09; Figure 5 ). Chronic infusion of Ang II caused significant increases in urinary excretion of PGE 2 metabolite in WT mice of both strains (DBA: 1968Ϯ498 pg/mg creatinine, PϽ0.01 versus baseline; 129: 3962Ϯ1022 pg/mg creatinine, PϽ0.001 versus baseline; Figure 5 ). The levels of PGE 2 metabolite in urine during Ang II infusion tended to be higher in the WT 129 compared to WT DBA/1; however, this difference did not achieve statistical significance. As shown in Figure 5 , the increased PGE 2 excretion during Ang II-dependent hypertension was attenuated in the mPGES1 Ϫ/Ϫ animals of both strains compared to WT controls, although, again, the difference between 129-WT and mPGES1 We next measured urinary excretion of TxB 2 , the stable metabolite of the potent vasoconstrictor prostanoid TxA 2 ( Figure 6, top graphs) , which has been implicated in the pathogenesis of Ang II-dependent hypertension. 34 -36 At baseline, there were no differences in excretion of urinary TxB 2 between WT DBA/1 and 129 mice (1542Ϯ391 versus 1976Ϯ529 pg/mg creatinine). On the DBA/1 background, absence of mPGES1 has no effect on TxB 2 excretion at baseline (1376Ϯ232 versus 1542Ϯ391 pg/mg creatinine, PϭNS), whereas urinary TxB 2 was higher in 129-mPGES1 Ϫ/Ϫ mice compared to the 129 WT controls, although the difference was not statistically significant (3402Ϯ796 versus 1976Ϯ529: Pϭ0.074). As shown in Figure 6 (top graphs), chronic infusion of Ang II had no effect on urinary TxB 2 excretion in the DBA lines (WT 1542Ϯ391 to 1319Ϯ172 pg/mg creatinine, PϭNS; mPGES1 Ϫ/Ϫ 1376Ϯ232 to 1488Ϯ300 pg/mg creatinine, PϭNS). In marked contrast, there were significant increases in urinary TxB 2 excretion with Ang II infusion by 2-fold in 129 WT (1976Ϯ529 to 4043Ϯ1077 pg/mg creatinine, Pϭ0.047) and more than 4-fold in 129 mPGES1 Ϫ/Ϫ mice (3402Ϯ796 to 14235Ϯ3948 pg/mg creatinine, Pϭ0.002) ( Figure 6 , top right).
We measured urinary excretion of 6-keto-PGF 1␣ , the stable metabolite of prostacyclin, a potent vasodilator and antithrombotic prostanoid (Figure 6, bottom) . At baseline, excretion of urinary 6-keto-PGF 1␣ was very similar in all 4 experimental groups, and there was no difference in excretion of the PGI 2 metabolite between WT and mPGES1-deficient mice on the DBA/1 (5350Ϯ1264 versus 6948Ϯ924 pg/mg creatinine, PϭNS) or 129 backgrounds (5223Ϯ1291 versus 5218Ϯ1153, PϭNS). As shown in Figure 6 , urinary 6-keto-PGF 1␣ excretion in the DBA lines was virtually unaffected by chronic infusion of Ang II (WT 5350Ϯ1264 to 4375Ϯ670 pg/mg creatinine, PϭNS; mPGES1 Ϫ/Ϫ 6948Ϯ924 to 6145Ϯ1108 pg/mg creatinine, PϭNS). By contrast, there were significant increases in urinary 6-keto-PGF 1␣ excretion with Ang II infusion by more than 3-fold in 129 WT (5223Ϯ1291 to 17836Ϯ4088 pg/mg creatinine, PϽ0.01) and by nearly 7-fold in 129 mPGES1 Ϫ/Ϫ mice (5218Ϯ1153 to 35517Ϯ5463 pg/mg creatinine, PϽ0.001).
We next measured mRNA levels for the COX enzymes COX-1 and -2 ( Figure 7 ). At baseline, the relative expression of COX-1 in the kidney was not significantly different between WT and mPGES1-deficient mice from both strains (100Ϯ13 versus 130Ϯ17% for DBA/1 and 100Ϯ9 versus 73Ϯ5% of WT for 129). Infusion of Ang II did not affect COX-1 mRNA abundance in the DBA/1 mice (WT 111Ϯ26 versus mPGES1 Ϫ/Ϫ 116Ϯ22% of WT baseline). In contrast, COX-1 mRNA levels increased with Ang II infusion by Ϸ50% in both 129 WT (150Ϯ21% of WT baseline, PϭNS) and mPGES1 Ϫ/Ϫ animals (146Ϯ21% of WT baseline, PϽ0.05), although this increase was statistically significant only in the mPGES1 Ϫ/Ϫ group. As shown in Figure 7 , baseline COX-2 expression was 2-fold higher in kidneys of DBA/1 mPGES1 Ϫ/Ϫ animals than their WT controls (100Ϯ18 versus 204Ϯ38% of WT; PϽ0.05), but there was no difference in COX-2 mRNA levels in the 129 mPGES1 Ϫ/Ϫ mice at baseline (100Ϯ29 versus 147Ϯ6% of WT; Pϭ0.061). Ang II infusion did not significantly alter COX-2 mRNA abundance in either group of DBA/1 mice (WT 163Ϯ18 versus mPGES1
Ϫ/Ϫ 184Ϯ39% of WT baseline), whereas COX-2 mRNA levels increased 2-fold with Ang II infusion in both 129 WT (197Ϯ43% of WT baseline, PϭNS) and mPGES1 Ϫ/Ϫ animals (279Ϯ36% of WT baseline, PϽ0.05), but this increase was statistically significant only in the 129-mPGES1 Ϫ/Ϫ group.
Discussion
A role for PGE 2 in blood pressure homeostasis was first suggested by studies documenting its vasodilator actions in the systemic circulation. 37, 38 Infusion of PGE 2 into the kidney commonly causes renal vasodilation. 39, 40 Moreover, relative to other COX products, PGE 2 is generated in substantial quantities by the kidney, where it is has potent natriuretic effects. The major sites of PGE 2 generation by the kidney are renal medullary interstitial cells and collecting duct. 8, 41, 42 This segment of the nephron plays a critical role in the final adjustments of sodium excretion that have a major impact on fluid volume and blood pressure homeostasis.
To examine the contributions of PGE 2 to blood pressure homeostasis, mice lacking mPGES1 have been used. We previously found that the absence of mPGES1 in mice on an inbred DBA/1 background had no effect on blood pressures during feeding of normal (0.4% NaCl) or high (6% NaCl) salt diets. 21 These findings were similar to the report from the FitzGerald group demonstrating normal blood pressures in mice lacking mPGES1. 22 By contrast, Yang and colleagues found that mPGES1-deficient mice developed hypertension with high salt feeding. 24 Moreover, they also reported that mPGES1-deficient mice were more susceptible to hypertension caused by chronic infusion of Ang II, manifesting exaggerated oxidative stress in this setting. 25 On the other hand, subsequent work by FitzGerald and colleagues showed that deletion of mPGES1 in low-density lipoprotein receptordeficient mice does not affect their hypertensive response to chronic infusions of Ang II but protects them from aortic aneurysm formation and significantly reduces oxidative stress. 23 The reasons for the differing outcomes of these studies of mPGES1-deficient mice are not clear. Because the strain combinations are different in each of the mPGES1-deficient lines from these studies, the effects of genetic 
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background to influence the mPGES1 phenotype may be one factor explaining the different phenotypes.
To evaluate the potential for strain-specific factors to modify the phenotype of mPGES1 deficiency, we generated mice lacking mPGES1 on 2 distinct genetic backgrounds: DBA/1lacJ and 129/SvEv. DBA/1 mice are susceptible to the development of collagen-induced arthritis, and 129 mice are salt-sensitive with enhanced susceptibility to kidney injury. 17,26 -28 We found that WT 129/SvEv mice have higher baseline blood pressure than WT DBA/1lacJ animals. Although deletion of mPGES1 had no effect on blood pressure on the DBA/1 background, blood pressures were significantly higher in mPGES1-deficient 129 mice compared to the 129 WT controls. Thus, genetic background significantly modifies the consequences of mPGES1 deficiency on baseline blood pressure.
Along with the effects on baseline blood pressure, the 129 background also proved more susceptible to the development of hypertension. Whereas the mPGES1-deficient mice on the DBA/1 background had blood pressure responses to chronic Ang II infusion that were virtually identical to the DBA/1 WT group, the severity of hypertension was substantially augmented in the 129-mPGES1 Ϫ/Ϫ mice compared to the 129 WT controls (Figure 2 ). Our findings are generally consistent with previous studies indicating that there are strain-specific genetic modifiers enhancing susceptibility to hypertension in 129 mice. 28, 43, 44 Moreover, our studies indicate a significant impact of mPGES1 to attenuate hypertension in the 129 but not the DBA/1 strain. This may explain some of the inconsistencies in blood pressure phenotypes previously reported for mPGES1-deficient mouse lines, which consisted of varying contributions from DBA/1 and 129 backgrounds. 20 -25 Enhanced hypertension in the 129 animals was also accompanied by exaggerated kidney injury as reflected by increased albumin excretion during Ang II infusion. This was apparent in the 129 WT mice compared to the WT DBA/1 group, consistent with enhanced susceptibility to kidney injury that has been observed in this strain. 26 -28 Furthermore, albuminuria induced by Ang II infusion was dramatically enhanced in the mPGES1-deficient 129 mice. Because the extent of blood pressure elevation was also more severe in the 129-mPGES1 Ϫ/Ϫ , it is not clear whether the worsening proteinuria was attributable to more severe hypertension or reflected a vulnerability to kidney damage caused by the absence of mPGES1. By contrast, DBA/1 WT mice developed only modest albuminuria during Ang II infusion, and this was not augmented in the DBA/1-mPGES1 Ϫ/Ϫ animals. These findings show that actions of mPGES1 to protect against kidney injury are also conditioned by genetic background. PGE 2 synthesis is stimulated during hemodynamic stress, and it has been suggested that increased levels of PGE 2 may be a compensatory response to attenuate the development of hypertension. 45 Chronic infusion of Ang II stimulated increased urinary excretion of PGE metabolite in WT mice of both DBA/1 and 129 strains. Elimination of mPGES1 significantly attenuated PGE 2 metabolite excretion by a similar amount (Ϸ60%) in mPGES1-deficient mice on both DBA and 129 backgrounds ( Figure 5 ). Thus, mPGES1 plays a significant role to increase PGE 2 production in response to Ang II. However, there is significant residual production of PGE 2 in both lines of mPGES1 Ϫ/Ϫ mice, suggesting that there are robust pathways for PGE 2 synthesis in vivo that do not require mPGES1. Despite a similar diminution of PGE 2 excretion and higher absolute levels of urinary PGE 2 metabolite with Ang II infusion in mPGES1 Ϫ/Ϫ animals on the 129 background, hypertension was significantly more severe in the 129 compared to DBA/1 mice. Accordingly, the different blood pressure responses cannot be explained by differences in PGE 2 metabolism.
Altered generation of other prostanoids, such as the potent vasoconstrictor TxA 2 , 34 -36 might explain the variable blood pressure responses that we observed. At baseline, urinary excretion of TxB 2 , the stable metabolite of TxA 2 , was similar in all of the DBA/1 and 129 lines. Ang II had no effect on urinary TxB 2 levels in DBA/1 mice but stimulated urinary TxB 2 excretion in the 129 mice that was more marked in the 129-mPGES1-deficient mice to levels that were much more pronounced than any of the other experimental groups. The general patterns for urinary excretion patterns of 6-keto-PGF 1␣ , the major metabolite of PGI 2 , resembled those for thromboxane. The more marked stimulation of thromboxane and prostacyclin with Ang II in the 129 strain mice was mirrored by increased expression of both COX isoforms.
The precise cause of enhanced susceptibility to hypertension in the 129-mPGES1 Ϫ/Ϫ mice is not completely clear from our studies. Although this cannot be explained by altered renin responses, differences in COX expression and prostanoid production in response to Ang II were quite marked between the 129 and DBA/1 lines. In particular, we speculate that augmented generation of thromboxane may contribute to the severity of hypertension in 129 mPGES1 Ϫ/Ϫ mice because previous studies by our group using thromboxane receptor-deficient mouse lines have shown that enhanced generation of TxA 2 contributes to blood pressure elevation and end-organ damage in Ang II-dependent hypertension. 34 However, the physiological consequences of altered prostanoid generation are complex and are likely determined by the balance of vasoconstrictor and vasodilator prostanoids at key tissue sites. In this regard, the ratio of TxB 2 /PGE 2 is increased more than 9-fold in the 129-mPges1 Ϫ/Ϫ mice compared to only 2-fold in the 129 WT controls. This indicates a tendency toward enhanced thromboxane generation in the mPGES1-deficient mice on the 129 strain mice that could contribute to their susceptibility to develop hypertension.
Expression of mPGES1 is enhanced in inflammatory states, and this is likely responsible for the increased production of PGE 2 that accompanies inflammation. Studies in mice lacking individual E-prostanoid receptor isoforms suggest that PGE 2 is responsible for inflammatory pain 46 and fever. 47 It is perhaps not surprising that genetic deletion of mPGES1 recapitulates many of the beneficial antiinflammatory actions of NSAIDs. Accordingly, it has been suggested that small molecule inhibitors of mPGES1 might be useful antiinflammatory agents encompassing the beneficial effects of NSAIDs without the associated cardiovascular hazard. With regard to the propensity to cause hypertension, our study suggests that the impact of mPGES1 blockade on blood pressure may be influenced by genetic background and associated stimulation of TxA 2 production. Perspectives mPGES1 inhibitors have been proposed as a potential new class of NSAIDs with fewer cardiovascular side effects compared to traditional NSAIDs or selective COX-2 inhibitors. Our data suggest that inhibiting mPGES1 may produce variable cardiovascular effects depending on genetic and environmental factors. Identification of genetic variables that influence the renal and cardiovascular response to mPGES1 inhibition may facilitate safe and effective therapies targeting this enzyme. 
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